Introduction {#s1}
============

Neonatal sepsis contributes substantially to neonatal morbidity and mortality, and is an ongoing major global public health challenge.[@R1] According to the onset of age, neonatal sepsis is divided into early-onset sepsis (EOS) and late-onset sepsis (LOS). EOS reflects transplacental or, more frequently, ascending infections from the maternal genital tract, whereas LOS is associated with the postnatal nosocomial or community environment, with the peak incidence reported to be between the 10th and 22nd day of life.[@R2] Since the early 1980s, epidemiological studies have observed a general reduction in EOS, probably due to advances in obstetric care and the use of prophylactic intrapartum antibiotics to prevent infections caused by Group B *Streptococcus*.[@R6] [@R7] Meanwhile, the incidence of LOS has increased in parallel with the improved survival of premature infants, especially in those with very low birth weight (VLBW), indicating the role of hospitalisation and life-sustaining medical devices in the pathogenesis of neonatal LOS.[@R6] [@R7] The microbial characteristics of LOS are of primary importance in guiding clinical antisepsis practice, and strategies to prevent and treat neonatal LOS may, in turn, influence the pattern of LOS pathogens. An up-to-date and thorough understanding of the epidemiology and management of neonatal LOS may help to reduce the burden of this disease.

Epidemiological and clinical aspects of LOS {#s2}
===========================================

The onset of LOS is most frequently defined at 72 h after birth, a cut-off time point considered to adequately differentiate LOS from EOS in terms of the spectrum of causative pathogens ([table 1](#FETALNEONATAL2014306213TB1){ref-type="table"}).[@R2] [@R7] As demonstrated in [table 2](#FETALNEONATAL2014306213TB2){ref-type="table"}, the incidence of LOS is inversely associated with birth weight (BW). Similarly, 36.3% of neonates with gestational age (GA) \<28 weeks had at least one episode of LOS, as compared with 29.6%, 17.5% and 16.5% of moderately preterm (GA of 29--32 weeks), late preterm (GA of 33--36 weeks) and term infants.[@R4] Apart from immaturity, other well-recorded risk factors for LOS include the long-term use of invasive interventions, such as mechanical ventilation and intravascular catheterisation, the failure of early enteral feeding with breast milk, a prolonged duration of parenteral nutrition, hospitalisation, surgery and underlying respiratory and cardiovascular diseases.[@R2] [@R4] [@R11] [@R13] [@R14] It should be noted that genetic factors, such as the polymorphism in immunity-associated genes may also be implicated in neonatal susceptibility to LOS.[@R2]

###### 

Recent epidemiological data on the incidence of neonatal late-onset sepsis (LOS)

  Author and country                                                        No. of centres   Birth year of cohort   No. of neonates   Definition of the onset of LOS   LOS, No. (%)   Proportion (%) of CONS
  ------------------------------------------------------------------------- ---------------- ---------------------- ----------------- -------------------------------- -------------- ------------------------
  VLBW infants                                                                                                                                                                        
  Boghossian *et al*,[@R2] USA                                              6                2002--2008             15 178            72 h                             3797 (25.0)    53.2
  Lahra *et al*,[@R9] Australia                                             1                1992--2004             798               48 h                             220 (27.6)     64.4
  Tröger *et al*,[@R11] Germany                                             46               2003--2011             5886              72 h                             882 (15.0)     58.4
  All admitted neonates                                                                                                                                                               
  Vergnano *et al*,[@R3] England                                            12               2006--2008             14 225            48 h                             868 (6.1)      54
  van den Hoogen *et al*,[@R8] Netherland                                   1                2003--2006             2278              48 h                             318 (13.9)     77.9
  Shim *et al*,[@R7] Korea                                                  1                1996--2005             1479              96 h                             134 (9.1)      6.2
  Morioka *et al*,[@R12] Japan                                              5                2006--2008             6894              72 h                             42 (0.61)      11.9
  Al-Taiar *et al*,[@R10] China (Hebei), Malaysia, Hong Kong and Thailand   4                2006--2009             36 842            72 h                             782 (2.12)     42.2
  Tsai *et al*,[@R4] Taiwan                                                 1                2004--2011             5010              6 days                           713 (14.2)     39.9
  Hammoud *et al*,[@R5] Kuwait                                              1                2005--2009             12 987            6 days                           949 (7.3)      35.5
  Leal *et al*,[@R13] Mexico                                                1                2004--2007             11 790            72 h                             78 (0.66)      47.4

CONS, coagulase-negative staphylococci; VLBW, very low birth weight.

###### 

Incidence of LOS by birth weight

  Reference                        Birth weight (g)   No. of neonates   LOS, No. (%)
  -------------------------------- ------------------ ----------------- --------------
  Boghossian *et al*,[@R2] USA     400--500           223               146 (65.5)
  501--750                         2680               1372 (51.2)       
  751--1000                        4030               1309 (32.5)       
  Vergnano *et al*,[@R3] England   1000--1499         1110              113 (10.2)
  1500--2500                       2945               66 (2.2)          
  \>2500                           5340               88 (1.6)          

LOS, late-onset sepsis.

Coagulase-negative staphylococci (CONS) have emerged as the predominant pathogens of LOS, accounting for 53.2%--77.9% of LOS in industrialised countries and 35.5%--47.4% in some developing regions ([figure 1](#FETALNEONATAL2014306213F1){ref-type="fig"}).[@R2] [@R7] In terms of toxin production, CONS are not so virulent as Gram-negative bacteria and fungi, which partly explains the lower rate of short-term infectious complications as well as mortality associated with CONS sepsis.[@R4] However, the risk of neurodevelopment sequelae, such as cognitive and psychomotor impairment, cerebral palsy, and vision impairment was independent of the type of pathogen, indicating that CONS are capable to exert a long-term detrimental effect on the host, particularly on the most immature infants with a BW\<1000 g.[@R15] Recent data shows that CONS, predominantly *Staphylococcus epidermidis*, is highly variable in genetic background and can acquire pathogenic determinants, such as the capability to establish biofilms and antimicrobial resistance in order to become better adapted to the nosocomial environment.[@R16] Epidemiological studies in the past decade showed that the most widespread *S. epidermidis* clone in hospitals is characterised by biofilm-forming capability.[@R16] Furthermore, CONS isolates from neonatal intensive care units (NICU) have become increasingly resistant to vancomycin, and strains with antiseptic resistance were also reported.[@R17] [@R18]

![Major causative pathogens of neonatal late-onset sepsis and their incidence by geographical areas.](fetalneonatal-2014-306213f01){#FETALNEONATAL2014306213F1}

Gram-negative bacilli responsible for neonatal LOS mainly include *Escherichia coli*, *Klebsiella* spp., *Enterobacter* spp. and *Pseudomonas* spp. ([figure 1](#FETALNEONATAL2014306213F1){ref-type="fig"}). Fungi, especially *Candida* spp., were reported to be one of the major pathogens for LOS in some regions.[@R7] [@R13] The distribution pattern of causative pathogens varies across regions and may change over time within the same hospital due to demographic characteristics of patients, microflora colonisation of the nosocomial environment and the policy of antibiotic use.[@R7] It should be noted that application of broad-spectrum antibiotics in the past decades has contributed to an increasing incidence of multidrug-resistant Gram-negative bacilli (MDR GNB), which account for approximately 20% of bacteraemia cases, and are associated with a 2.8-fold increase in neonatal mortality rate than are non-MDR strains.[@R19]

New approaches to diagnose neonatal LOS {#s3}
=======================================

Blood culture remains as the definitive diagnostic tool for neonatal sepsis. However, this 'gold standard' testing method is time-consuming and may produce false positive results as well as false negative results, which can be attributed to the difficulties in discriminating a true CONS infection from sample contamination.[@R20] A timely and accurate diagnosis of LOS is of utmost importance, given the mortality rate and long-term adverse outcomes associated with LOS.

The inherent limitations of blood culture technique have given impetus to an extensive search of biomarkers for diagnosing neonatal LOS.[@R20] To qualify as an ideal biomarker, many criteria need to be satisfied, such as a small blood volume, high sensitivity and specificity, high positive and negative predicative values, short laboratory turnaround time, 24 hours bedside availability and a reasonable price. Up to now, no single biomarker has been identified to fulfil most, if not all, these criteria. The combination of multiple biomarkers, such as the total number of neutrophils, immature to total neutrophil ratio and C-reactive protein (CRP) holds promise to enable a fast and accurate diagnosis of LOS.[@R21] Sequential detection of CRP may help to rule out microbial infections in a timely manner, facilitating an early cessation of antibiotic treatment.[@R20]

Recently, molecular-based methods have emerged as promising diagnostic tools for neonatal sepsis. PCR, a technology based on the extraction of microbial DNA from blood samples and the subsequent sequencing or hybridisation of species-specific gene regions, is widely investigated for the detection of micro-organisms.[@R22] [@R23] Furthermore, real-time PCR which focuses on the temporal measurement of fluorescent signals generated in each amplification cycle, has been explored to monitor the microbial load and rapidly target specific micro-organisms in clinical specimens.[@R23] Compared with the conventional culture technology, PCR technologies yield results with a higher sensitivity, a much smaller sample volume and less laboratory turnaround time. Recently developed PCR-based diagnostic platforms are highlighted by a low contamination rate, with DNA extraction, multiplex PCR and detection of PCR products performed in a closed system.[@R24] This design can help to differentiate potential contamination from true positive cases, particularly for the detection of CONS, since CONS from the patients, nurses taking the blood sample and laboratory personnel may cause contamination.[@R22] Another inspiring development in the field of molecular assays is microarray, which is characterised by the hybridisation of clinical samples on a glass or silicon slide preloaded with an array of protein or nucleic acid products.[@R23] [@R25] This technology allows us to simultaneously detect pathogens, microbial virulence and even the host immune response profile.[@R23] [@R25] Although highly sensitive and specific, microarray cannot replace the conventional method of culture in the isolation of pathogens and the subsequent detection of antibiotic-resistance profile.[@R23] The requirement for special instruments and highly trained staff is also one limitation that needs to be addressed.[@R22] [@R23]

Clinical signs of neonatal LOS are generally regarded as non-specific and inconspicuous. Recent studies show that monitoring physiological data constantly displayed in neonates is a promising method to predict proven or clinical sepsis.[@R26] The greatest advance in this field is the monitoring of heart rate characteristics (HRC), and the rationale is that reduced variability and transient decelerations in heart rate, partly mediated by inflammatory cytokines, indicate a high chance of imminent sepsis.[@R26] A large randomised trial found a good agreement between expected and proven sepsis by HRC monitoring, and the sepsis-associated mortality was significantly reduced in neonates whose HRC was displayed as compared with the control (10% vs 16.1%, p=0.01).[@R27] Ongoing research combining HRC and other physiological data, such as respiratory rate and blood pressure, may provide more advanced algorithms for an early diagnosis of LOS.[@R26]

Prevention of neonatal LOS {#s4}
==========================

Given that the treatment of sepsis does not always protect infants from the risk of long-term neurodevelopmental impairments, the best strategy is to prevent rather than to treat LOS.[@R28] So far, adherence to infection control protocols remains to be the cornerstone of LOS prevention. By implementing bundles of evidence-based strategies, namely hand hygiene, full-barrier precautions, 2% chlorhexidine skin antiseptics, avoidance of the femoral route and prompt removal of unnecessary catheters, combined with cultural and behavioural support, the *Matching Michigan* initiative resulted in a remarkable 47.3% decrease in the rate of bloodstream infections from central venous catheters in 19 paediatric ICUs in England.[@R29] Standardised catheter care bundles used among 24 Ohio NICUs were also shown to be effective by reducing 20% of LOS.[@R30] Because nearly one-third of LOS were not associated with intravascular catheters, improvement may require other preventive measures, such as the use of prenatal steroids, reduction of assisted mechanical ventilation, early application of continuous positive airway pressure, early surfactant administration and optimal feeding strategies.[@R31] Additionally, nationwide surveillance systems can contribute to the reduction of neonatal LOS by providing ongoing surveillance data for quality management and benchmarking between institutions.[@R32]

Of note, interdisciplinary collaborations at the interface of microbiology and immunology have recently inspired new strategies to prevent neonatal LOS.

Probiotics {#s4a}
----------

Gut microbiome is the complex and dynamic population of several hundred bacterial species colonising in the gut. It has been increasingly recognised as an essential 'organ' of newborns in delivering nutrients, regulating epithelial maturation and developing innate immune defence against infections.[@R33] [@R34] Vaginally delivered term infants are usually colonised by anaerobes, such as *Bacteroides* spp. and *E. coli* within days of birth, followed by a predominance of *Bifidobacterium* spp. and *Lactobacilli* spp. when breast feeding is initiated.[@R35] Caesarean section, prolonged antibiotic use, an extended stay in the healthcare environment and formula feeding can disturb the normal colonisation process.[@R36] VLBW infants were shown to have delayed colonisation of normal bacterial species, as well as less microbial diversity in the intestinal tract due to their frequent exposure to the above-mentioned risk factors.[@R36] [@R37] An abnormal gut microflora may compromise the integrity of intestinal barrier, causing bacterial translocation into the bloodstream.[@R38] CONS were identified to be a predominant species in the stool of VLBW neonates and were closely associated with LOS independent of the presence of indwelling devices, corroborating the role of gut as an important source of potential pathogens causing sepsis.[@R39] [@R40] The rationale of using probiotics, therefore, is to normalise the gut microbiome with exogenous micro-organisms which commonly comprise *Bifidobacterium* and *Lactobacillus* spp.[@R41] The potential benefits of probiotics conferred on the host are summarised in [table 3](#FETALNEONATAL2014306213TB3){ref-type="table"}. Although theoretically promising, the use of probiotics in clinical trials has revealed inconsistent results with regard to the prevention of nosocomial sepsis, and meta-analyses showed that probiotics did not significantly reduce the incidence of sepsis as compared with the controls.[@R41] [@R42] The lack of effect may be largely due to the heterogeneity among trials in terms of probiotic administration protocol (strains, dosage, frequency and duration), and more studies are required to determine the efficacy and safety of probiotics in infants.[@R37] [@R41]

###### 

Theoretical mechanisms of currently explored feeding strategies to prevent neonatal LOS

  Explored strategy                                                        Theoretical mechanisms
  ------------------------------------------------------------------------ ---------------------------------------------------------------------------
  Probiotics[@R37] [@R41]                                                  ↑ the intestinal mucosal barrier to prevent the translocation of bacteria
  Competitive exclusion of potential pathogens                             
  Produce bacteriocins that kill pathogens                                 
  ↑ immunoglobulin A mucosal responses                                     
  Modulation of host immune reactions to microbial products                
  ↑ enteral nutrition and gut maturation                                   
  Early enteral trophic feeding[@R44] [@R46]                               Prevent the atrophy of gastrointestinal mucosa
  ↑ the establishment of healthy gut microflora                            
  ↓ the use of parenteral nutrition by facilitating full enteral feeding   
  ↑ gut mucosal immunity                                                   
  Lactoferrin[@R28] [@R38]                                                 Antimicrobial effect by iron chelation
  Immunomodulatory function through cytokine production                    
  ↑ the growth of probiotic bacteria                                       
  ↑ the growth and differentiation of enterocytes                          
  ↓ the formation of reactive oxygen species                               

LOS, late-onset sepsis.

Early enteral trophic feeding with breast milk {#s4b}
----------------------------------------------

The initiation of enteral feeding is often delayed in VLBW neonates due to the concern that early enteral feeding may not be tolerated and may be implicated in the pathogenesis of necrotising enterocolitis (NEC).[@R43] [@R44] However, the lack of enteral feeds may hinder the functional maturation of the gastrointestinal tract, and the prolonged use of parenteral nutrition is associated with an increased risk of systemic infection due to the impairment of immune cell functions.[@R44] [@R45] Trophic feeding, also referred to as minimal enteral feeding and priming feeding, is generally defined as an enteral intake of breast milk and/or formula, with a small volume of up to 24 mL/kg/day.[@R43] [@R44] This strategy attempts to overcome the absence of enteral stimulation while exerting minimal stress on the immature gastrointestinal system.[@R46] Early trophic feeding, initiated within the first few days of birth, has shown benefits in the prevention of nosocomial infections without an increased risk of intestinal complications.[@R14] [@R46] [@R47] Breast milk, apart from its abundant nutrients, also contains secretory antibodies, immune cells, lactoferrin (LF) and prebiotics which can stimulate the growth of beneficial gut flora.[@R33] [@R48] Therefore, breast milk has been given priority over formula in the introduction of enteral trophic feeding due to its benefits on the promotion of neonatal immune functions.[@R43] [@R47] It is demonstrated that human milk feeding started within the first 72 h after birth was associated with an approximately threefold reduction in the risk of LOS.[@R47] Despite numerous studies, multiple factors of the feeding protocol, such as the time of initiation, method of administration and advance rate still remain controversial, and further trials are needed for protocol optimisation.[@R44]

Lactoferrin {#s4c}
-----------

LF, a major protein in human milk, performs multiple functions as an important component of innate immune defence against infections ([table 3](#FETALNEONATAL2014306213TB3){ref-type="table"}).[@R28] [@R38] Bovine lactoferrin (BLF) has been shown to significantly decrease the incidence of neonatal LOS as compared with placebo controls.[@R49] When combined with probiotics, BLF further enhanced its prophylactic effect on LOS, emphasising the synergistic action of LF and other antimicrobial agents.[@R49] However, there was a small number of preterm infants included in these trials, and further studies are warranted to fully assess the effectiveness and safety of LF in neonates by addressing its optimal dosage, duration of treatment and possible combination with probiotics.[@R28] The prophylactic use of LF cannot be recommended as routine yet.[@R50]

Immune replacement therapy {#s4d}
--------------------------

The immune system of neonates, especially the most immature ones, is characterised by a low neutrophil storage pool and rapid exhaustion of bone marrow reserve during sepsis.[@R23] As a consequence, neutropenia may ensue.[@R23] Additionally, an inadequate transplacental transport of maternal immunoglobulin G results in a prolonged immunoglobulin deficiency at birth, which is further aggravated during the first month in life.[@R31] Based on this knowledge, immune replacement therapies were widely explored in the hope of correcting the immune deficiencies and thus preventing neonatal infections. Colony-stimulating factors (CSF), such as granulocyte CSF and granulocyte-macrophage CSF, are cytokines that promote the proliferation and antimicrobial function of neutrophils, monocytes and macrophages.[@R51] [@R52] However, there was no significant difference in sepsis-free survival between the intervention group and placebo group ([table 4](#FETALNEONATAL2014306213TB4){ref-type="table"}).[@R51] [@R52] Intravenous immunoglobulins (IVIG), which can enhance opsonic activity, complement activation, antibody-dependent cytotoxicity and neutrophil phagocytosis, showed no prophylactic effect on neonatal sepsis.[@R53] It is noteworthy, that IVIG treatment of neonates with suspected or proven sepsis also failed to reduce the mortality in a large multicentre trial.[@R54] Moreover, INH-A21, a specific antistaphylococcal immunoglobulins against *S. epidermidis* and *Staphylococcus aureus*, demonstrated no significant effect to prevent neonates against sepsis despite its theoretical value.[@R55] 

###### 

Trials for prevention of late-onset sepsis in very low birth weight neonates

  Trial of example                Birth year of cohort   Therapy           No. of infants                                                                                                  
  ------------------------------- ---------------------- ----------------- --------------------- ------------------------- --------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  Immune replacement therapy                                                                                                                                                               
   Carr *et al*[@R52]             2000--2006             GM-CSF            139                   141                       Sepsis-free survival rate                                       66.9% vs 74.5%, difference: −8%, 95% CI −18 to 3
   Kuhn *et al*[@R51]             2002--2006             G-CSF             102                   98                        Sepsis-free survival rate                                       73% vs 67%, p=0.42
   Fanaroff *et al*[@R53]         1988--1991             IVIG              1204                  1212                      Incidence of sepsis                                             15.5% vs 17.2%, RR: 0.9, 95% CI 0.75 to 1.08
   DeJonge *et al*[@R55]          2004--2006             INH-A21           994                   989                       Incidence of sepsis                                             27% vs 29%, p=0.2
  Feeding strategies                                                                                                                                                                       
   Jacobs *et al*[@R42]           2007--2011             Probiotics\*      548                   551                       Incidence of sepsis                                             13.1% vs 16.2%, p=0.16
    Flidel-Rimon *et al* [@R46]   1995--2001             Enteral feeding   385†                                            The relationship between the initiation of feeding and sepsis   Enteral feeding was started at an earlier age in infants who did not develop sepsis (2.8 vs 4.8 days, p=0.0001)
   Manzoni *et al*[@R49]          2007--2008             BLF alone         153                   168                       Incidence of sepsis                                             5.9% vs 17.3%, p=0.002 
  BLF plus LGG                    151                    168               Incidence of sepsis   4.6% vs 17.3%, p\<0.001                                                                   
  Skin care with antiseptics                                                                                                                                                               
   Quach *et al*[@R57]            2009--2013             CHG bathing       195‡                                            Incidence of sepsis                                             Sepsis rate decreased in the period of CHG bathing (6.00 vs 1.92/1000 CVC-days; adjusted RR, 0.33, 95% CI 0.15 to 0.73)

\**Bifidobacterium infantis*, *Streptococcus thermophilus* and *Bifidobacterium lactis*.

†Grouping of neonates was based on the presence of sepsis.

‡The study used a before-and-after quasiexperimental design.

BLF, bovine lactoferrin; CHG, chlorhexidine gluconate; CVC, central venous catheter; GM-CSF, granulocyte-macrophage colony-stimulating factor; IVIG, intravenous immunoglobulins; LGG, *Lactobacillus rhamnosus*; G-CSF, granulocyte colony-stimulating factor; RR, relative risk.

The failure of immune replacement therapies in the prophylaxis of neonatal sepsis suggests that neonatal immunity is not simply immature, but rather specifically regulated for the early stage of postnatal life, and LOS should be managed based on the immunological specificities of neonates.[@R56]

Skin care with antiseptics {#s4e}
--------------------------

Neonates receiving intensive care, especially VLBW infants, are prone to be colonised by pathogenic organisms from the hospital environment. An immature skin barrier and frequent exposure to skin-disrupting procedures further contribute to their vulnerability to nosocomial pathogens. Antiseptics have been shown to reduce skin colonisation of pathogens.[@R57] [@R58] A meta-analysis on the use of Chlorhexidine gluconate (CHG), however, yielded no conclusive benefits of CHG bathing on sepsis prevention (pooled relative risk: 0.65, 95% CI 0.40 to 1.05).[@R58] It should be noted that there was a high between-trial heterogeneity with regard to CHG concentration, bathing frequency and patients' baseline characteristics.[@R58] Despite a scarcity of reported adverse events, CHG cleansing and bathing is associated with risks of skin irritation and toxic effects following the systemic absorption.[@R59] Other concerns are that CHG may raise skin pH in infants, thereby disturbing the physiological acidic milieu established on neonates' skin within days of birth. This so-called 'postnatal acid mantle' is important for metabolic activities of keratinocytes and the development of normal skin microflora.[@R60] CHG bathing may remove vernix caseosa, the biological functions of which include mechanical barrier protection and thermoregulation, as well as antimicrobial and immunomodulatory properties.[@R61] Furthermore, CHG may eliminate commensal bacteria on the skin and result in a microflora dominated by pathogenic organisms, predisposing the infant to infections.[@R62] So far, CHG bathing has not been recommended for routine use in neonates due to a lack of data on safety and efficacy.[@R59]

Antibiotic treatment of LOS {#s5}
===========================

Due to the potential negative outcomes associated with missed septic cases, empirical antibiotic treatment is initiated on suspicion of LOS. An ideal choice of antimicrobial agents is to cover the most common pathogens without providing selection pressure for antibiotic resistance.[@R63] Currently, the recommended first-line therapy is flucloxacillin (or ampicillin) combined with gentamicin.[@R62] Recent national surveillance data from UK showed that the vast majority of organisms isolated from LOS blood samples (95%--97%) were susceptible to gentamicin+ flucloxacillin and gentamicin+amoxicillin/penicillin, suggesting that the current guideline for empirical therapy is adequate and most LOS cases can be appropriately treated by narrow-spectrum antibiotics.[@R64] This may hold true for UK and some Western countries. However, in many countries and regions of the world, a different pattern of causative micro-organisms has been identified, and the first-line antibiotic regimen is required to be tailored to the local pathogenic epidemiology. The increasing number of multiresistant strains, especially in developing countries, is a serious matter of concern. As demonstrated by a study of four Asian units, 37% of all Gram-negative organisms were resistant to gentamicin and approximately one-third were resistant to both gentamicin and third-generation cephalosporins.[@R10] Similarly, 14.7% of all Gram-negative organisms isolated in a hospital in Kuwait were resistant to gentamicin, and a high rate of resistance to cephalosporin (41.8%) was observed.[@R5] A possible explanation is that alternatives to the choice of antibiotics are diverse in these regions and frequently incorporate third-generation cephalosporin, such as cefotaxime, in disregard of the recommended regimens.[@R10] [@R65] It is alarming that approximately 20% of neonatal units in UK and the Republic of Ireland use a cephalosporin, as shown by recent data.[@R65] Another concern is the increasingly resistant CONS, and the optimal trough vancomycin concentration has been increased from 5 μg/mL --10 μg/mL to 10 μg/mL --15 μg/mL in order to sustain an effective vancomcyin therapeutic range against CONS.[@R63] The application of broad-spectrum antibiotics is alerting due to its close association with multidrug-resistance, and it has been reiterated that the spectrum of antibiotics used for empirical therapies should be as narrow as possible.

Apart from the selection of antibiotics, duration of treatment is another important factor to consider in empirical antibiotic therapies. A prompt cessation of antibiotics is generally warranted if blood culture yields negative results after 36--48 h, and the infant shows no subsequent clinical evidence of sepsis or other neonatal infections.[@R63] [@R66] Although appropriately cautious, this practice still leads to unnecessary antibiotic exposure among many infants, since blood cultures are positive in only 5%--10% of suspected cases.[@R17] [@R21] It is alerting that antibiotics are overused in patients who did not actually develop LOS, leading to a higher risk of NEC or death (OR: 2.66, 95% CI 1.12 to 6.3) among them as compared with patients receiving no or limited antibiotics.[@R67] Since the antibiotic treatment of culture-proven sepsis is imperative and unavoidable, minimisation of empirical therapy in infants who have not actually developed sepsis or other neonatal infections contributes substantially to patients' welfare and may help to contain microbial susceptibility to antibiotic treatment.

Given the increasing resistance rate of pathogens and relatively slow development of novel antimicrobial agents, antibiotic stewardship programme (ASP) is designed and implemented to optimise antibiotic therapy.[@R63] [@R66] [@R68] Major strategies include:[@R63] [@R66] [@R68] (1) performing prospective audits with interventions and feedbacks; (2) cooperating with local microbiology and infection control staff to regularly monitor the adequacy of antibiotic regimens, because the pattern of causative pathogens and antibiotic resistance profile may change over time and vary geographically; (3) avoiding unnecessary use of broad-spectrum antibiotics in proven infections; (4) reducing antibiotic administration at the start of life and ensuring the cessation of empirical antibiotic treatment when negative blood culture results are obtained; (5) educating antimicrobial prescribers and documenting their compliance with the guidelines. To date, ASPs have shown positive impact on the quality of antibiotic use, with microbiological outcomes improved in 75% of the studies.[@R68]

Conclusion {#s6}
==========

The advance in neonatal intensive care medicine is a double-edged sword, with improved survival of neonates on one side and an increased rate of LOS on the other. The pathogen pattern of neonatal LOS changes with time and over regions, and should be regularly re-evaluated to guide the management of LOS. Despite all efforts, an early and accurate diagnostic tool for neonatal LOS is yet to be found. In the current empirical antibiotic regimen, ASPs should be implemented to avoid unnecessary usage of broad-spectrum antibiotics and a longer-than-needed duration of treatment. Up to now, the best strategy to treat neonatal LOS lies in prevention. Besides strict adherence to established infection control protocols and less invasive interventions in neonatal intensive care, current evidence shows that early feeding with breast milk is a promising measure to effectively prevent neonatal LOS.
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